Seeking Alpha

Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA...

Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA approved walking treatment for multiple sclerosis, also improves walking in patients with post-stroke deficits. ACOR says once it has completed its analysis it will consult with the FDA on developing the drug for use by stroke survivors. Shares +8.6% premarket. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|